FierceBiotech1d
Concentra curveball offer throws Acelyrin merger with Alumis into doubt
As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject ...
Alumis and Acelyrin sign merger agreement
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...
BioPharma Dive1d
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
Investing1d
ACELYRIN shares surge on buyout interest
The interest from Concentra Biosciences includes an offer to purchase all outstanding shares of ACELYRIN at $3.00 each, plus a contingent value right tied to 80% of net proceeds from potential future ...
Yahoo Finance3d
Acelyrin, Inc. (SLRN)
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...
BioPharma Dive15d
Immune drugmakers Alumis and Acelyrin to merge
The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...
Activist investor threatens Peninsula drug maker's merger plans
Here's how an activist investor is threatening a Peninsula drug maker's merger plans. And the drama introduces a potential ...